Uses of Growth and Differentiation Factor 8 (GDF-8)

• US 20140286916A1
• Filed: 10/10/2012
• Published: 09/25/2014
• Est. Priority Date: 10/11/2011
• Status: Abandoned Application

• Current Assignee: Bone Therapeutics SA (BioSenic SA)
• Original Assignee: Bone Therapeutics SA (BioSenic SA)
• Inventors: Albarani, Valentina, Bastianelli, Enrico, Bizimungu, Christelle, Joly, Alice, Nguyen, Xuan Mai, Tytgat, Isabelle
• Application Number:
  US14/351,249
• Publication Number:
  US 20140286916A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2035/122 for inducing tolerance or supression of immune responses
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/19 Growth and differentiation factors [GDF]
• CPC Class Codes: C12N 5/0654 Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

The present invention relates to uses of growth and differentiation factor 8 (GDF-8) in vitro or in vivo for reducing the immunogenicity or risk of rejection of cells such as in particular mesenchymal stem cells (MSC), tissues or materials. The present invention further relates to methods for differentiating MSC in vitro or ex vivo into osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells using FGF-2 and GDF-8. In addition, the present invention relates to osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells obtainable by such methods and to the osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells for use in the treatment of musculoskeletal diseases.

Claims

1. A method for reducing the immunogenicity of cells in vitro, the method comprising sing cells to growth and differentiation factor 8 (GDF-8), wherein the cells are selected from the group consisting of mesenchymal stem cells (MSC), cells obtained by differentiation of MSC, cells of osteocytic lineage, cells of chondrocytic lineage, cells of adipocytic lineage, cells of myocytic lineage, cells of tendonocytic lineage, cells of fibroblastic lineage, and cells of stromogenic lineage.

2. The method according to claim 1, wherein the cells of osteocytic lineage, cells of chondrocytic lineage, cells of adipocytic lineage, cells of myocytic lineage, cells of tendonocytic lineage, cells of fibroblastic lineage, or cells of stromogenic lineage are obtained by differentiation of MSC.

3. The method according to claim 1, wherein the cells are MSC, osteoprogenitors, osteoblastic cells, osteocytes, chondroblastic cells, chondrocytes, adipoblastic cells, adipocytes, myoblastic cells, or myocytes, preferably wherein the cells are MSC, osteoprogenitors, osteoblastic cells, chondroblastic cells, or chondrocytes.

4. The method according to claim 1, wherein the cells are MSC.

5. The method according to claim 1, wherein the cells are osteoprogenitors or osteoblastic cells.

6. The method according to claim 1, wherein the cells are mammalian cells such as human cells or non-human mammalian cells, preferably human cells.

7. The method according to claim 1, wherein GDF-8 reduces MHC class II cell surface receptor complex on the cells and optionally reduces one or more costimulatory factors on the cells.

8. The method according to claim 7, wherein on human cells the MHC class II cell surface receptor is human leukocyte antigen DR (HLA-DR).

9. The method according to claim 1, wherein the cells are comprised in an implant or transplant, preferably in an osseous and/or articular tissue implant or transplant, or in a pharmaceutical formulation.

10. A method for reducing the immunogenicity of cells with GDF-8 in vivo in a subject, the method comprising exposing cells in a subject to GDF-8 in vivo, wherein the cells are selected from the group consisting of MSC, cells obtained by differentiation of MSC, cells of osteocytic lineage, cells of chondrocytic lineage, cells of adipocytic lineage, cells of myocytic lineage, cells of tendonocytic lineage, cells of fibroblastic lineage, and cells of stromogenic lineage.

11. The method according to claim 10, wherein GDF-8 and the cells are administered to the subject in combination.

12. The method according to claim 10, wherein the cells comprise MSC, osteoprogenitors, osteoblastic cells, osteocytes, chondroblastic cells, chondrocytes, adipoblastic cells, adipocytes, myoblastic cells, or myocytes, preferably wherein the cells are MSC, osteoprogenitors, osteoblastic cells, chondroblastic cells, or chondrocytes.

13. The method according to claim 10, wherein the cells are allogeneic to the subject.

14. A method for treating a musculoskeletal disease in a patient in need thereof, the method comprising administering a combination of GDF-8 and cells to the patient,

wherein the cells are selected from the group consisting of MSC, cells obtained by differentiation of MSC, cells of osteocytic lineage, cells of chondrocytic lineage, cells of adipocytic lineage, cells of myocytic lineage, cells of tendonocytic lineage, cells of fibroblastic lineage, and cells of stromogenic lineage.

15. The method according to claim 14, wherein the cells comprise MSC, osteoprogenitors, osteoblastic cells, osteocytes, chondroblastic cells, chondrocytes, adipoblastic cells, adipocytes, myoblastic cells, or myocytes, preferably wherein the cells are MSC, osteoprogenitors, osteoblastic cells, chondroblastic cells, or chondrocytes.

16. The method according to claim 14, wherein the musculoskeletal disease is a bone disease or an osteoarticular disease, and wherein the cells are selected from the group consisting of MSC, cells of osteocytic lineage, cells of chondrocytic lineage, cells of myocytic lineage, and cells of tendonocytic lineage, preferably wherein the cells are MSC, osteoprogenitors, osteoblastic cells, osteocytes, chondroblastic cells, chondrocytes, myoblastic cells, or myocytes.

17. The method according to claim 14, wherein the cells are allogeneic to the patient to whom they are to be administered.

23. The method according to claim 14, wherein the musculoskeletal disease is a bone disease or an osteoarticular disease.

18. A method of reducing the risk of rejection by a patient of a material administered, implanted, or transplanted into the patient, the method comprising co-administering GDF-8 and the material to the patient.

19. A method according to claim 18, wherein the material comprises osseous and/or articular tissue.

20. A pharmaceutical composition comprising a material to be administered, implanted, or transplanted into a patient and GDF-8, and optionally further comprising one or more pharmaceutically acceptable excipients.

21. The pharmaceutical composition according to claim 20, wherein the material comprises cells selected from the group consisting of MSC, cells obtained by differentiation of MSC, cells of osteocytic lineage, cells of chondrocytic lineage, cells of adipocytic lineage, cells of myocytic lineage, cells of tendonocytic lineage, cells of fibroblastic lineage, and cells of stromogenic lineage.

22. The pharmaceutical composition according to claim 20, wherein the material comprises osseous and/or articular tissue.